ArticleJournal of biological engineering2025
Integration of TLR7/8 agonists into lipid nanoparticles enhances antigen-specific immune responses to N1-methyl-Ψ-modified mRNA-LNP vaccines.
Article in Journal of biological engineering, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Virus infections and cancers: from mechanisms to therapeutics.Molecular biomedicine · 2026Review
- Engineered Polylactic Acid (PLA) Microcapsules for Spatiotemporally Coupled Delivery and Synergistically Enhanced Dual Immunity.Pharmaceutics · 2026Article
- The evolution of vaccine strategies for colorectal cancer: from conventional approaches to the mRNA era.Frontiers in immunology · 2026Review
- TLR agonists as adjuvants for viral vaccines: mechanisms, applications, and future directions.Frontiers in microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
N1-methylpseudouridine (N1-methyl-Ψ)-modified mRNA offers a safer alternative to unmodified mRNA-based cancer immunotherapies but induces weaker innate immune responses. This study aimed to enhance the expression of N1-methyl-Ψ-modified mRNA and improve innate and adaptive immune responses by incorporating a toll-like receptor (TLR) 7/8 agonist (AD7/8) into a lipid nanoparticle (LNP). AD7/8 was incorporated into LNPs by partially replacing cholesterol, and the mRNA expression efficiency of various formulations was evaluated, leading to the selection of the LNP formulation containing 0.5% AD7/8 (AD03-LNP). AD03-LNP was evaluated using mRNAs encoding human papillomavirus (HPV)16 E7 and HPV18 E6 antigens, the SARS-CoV-2 Omicron spike protein (S-Omicron), and influenza hemagglutinin (HA), and it consistently enhanced antigen-specific immune responses compared with conventional LNP. In the HPV mRNA model, antigen-specific CD8⁺ T cell and cytokine responses were significantly increased by 1.5-2.1-fold. In the S-Omicron mRNA model, IgG2a levels, indicative of a Th1-skewed response, were markedly elevated by 8-fold as measured by endpoint titers. Importantly, in the HA mRNA model, which evaluated both cellular and humoral immunity, AD03-LNP induced significantly higher CD8⁺ T cell responses by 2.3-2.6-fold, together with increased antibody production, with total IgG elevated by 3.6-fold as measured by endpoint titers. These findings demonstrate that AD03-LNP enhances both cellular and humoral immune responses across diverse antigens. These results provide insights into how TLR7/8 agonist-loaded LNPs influence mRNA expression and immune responses, supporting an effective formulation approach to boost the immunogenicity of mRNA-LNP vaccines. This approach may help advance the design of mRNA-based cancer immunotherapies and prophylactic vaccines that depend on strong T cell responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.